GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » Earnings per Share (Diluted)

Guided Therapeutics (Guided Therapeutics) Earnings per Share (Diluted) : $-0.05 (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics Earnings per Share (Diluted)?

Guided Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.05.

Guided Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.05.

Guided Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.05.

During the past 3 years, the average EPS without NRIGrowth Rate was 26.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 89.20% per year.

During the past 13 years, Guided Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 99.80% per year. The lowest was -68.80% per year. And the median was 64.75% per year.


Guided Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Guided Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guided Therapeutics Earnings per Share (Diluted) Chart

Guided Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.58 -0.04 -0.18 -0.15 -0.07

Guided Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.01 - -0.01

Competitive Comparison of Guided Therapeutics's Earnings per Share (Diluted)

For the Medical Devices subindustry, Guided Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's PE Ratio falls into.



Guided Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Guided Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.489-0.171)/51.131
=-0.07

Guided Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.402-0.039)/54.750
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Guided Therapeutics  (OTCPK:GTHP) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Guided Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Guided Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Guided Therapeutics (Guided Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
Executives
John E Imhoff director, 10 percent owner P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic director 349 FORBES AVE, SAN RAFAEL CA 94901
Michael C James director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Richard P. Blumberg director 2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff 10 percent owner 2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright officer: Chief Executive Officer 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp. 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock director 5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff director C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen director P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot officer: VP of R & D 4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071

Guided Therapeutics (Guided Therapeutics) Headlines